TY - JOUR
T1 - Intrahepatic cholangiocarcinoma
T2 - Molecular markers for diagnosis and prognosis
AU - Rahnemai-Azar, Amir A.
AU - Weisbrod, Allison
AU - Dillhoff, Mary
AU - Schmidt, Carl
AU - Pawlik, Timothy M.
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver tumor with increasing incidence worldwide. The outcome of patients with iCCA is dismal owing to tumor's aggressiveness, late diagnosis and lack of effective treatment options. Detection of the tumor at early stages may make surgical resection, as only potential curative treatment, more feasible. Unfortunately, despite recent developments in imaging modalities and laboratory tests, the diagnosis of iCCA remains challenging and patients often present in advanced stages when surgery cannot be offered. Moreover, accurate assessment of disease burden is critical to optimize management strategy, including the use of adjuvant therapies and clinical trials. Identifying iCCA specific diagnostic and prognostic biomarkers has been a focus of interest among many investigators with a progressive increase in data on iCCA related to advances in “omics” technologies. We herein summarize iCCA biomarkers and define the molecular mechanisms underlying iCCA carcinogenesis, as well as highlight potential diagnostic and prognostic application of molecular biomarkers.
AB - Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver tumor with increasing incidence worldwide. The outcome of patients with iCCA is dismal owing to tumor's aggressiveness, late diagnosis and lack of effective treatment options. Detection of the tumor at early stages may make surgical resection, as only potential curative treatment, more feasible. Unfortunately, despite recent developments in imaging modalities and laboratory tests, the diagnosis of iCCA remains challenging and patients often present in advanced stages when surgery cannot be offered. Moreover, accurate assessment of disease burden is critical to optimize management strategy, including the use of adjuvant therapies and clinical trials. Identifying iCCA specific diagnostic and prognostic biomarkers has been a focus of interest among many investigators with a progressive increase in data on iCCA related to advances in “omics” technologies. We herein summarize iCCA biomarkers and define the molecular mechanisms underlying iCCA carcinogenesis, as well as highlight potential diagnostic and prognostic application of molecular biomarkers.
KW - Biliary tract cancer
KW - Biomarkers
KW - Diagnosis
KW - Intrahepatic cholangiocarcinoma
KW - Molecular pathogenesis
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85013680737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013680737&partnerID=8YFLogxK
U2 - 10.1016/j.suronc.2016.12.009
DO - 10.1016/j.suronc.2016.12.009
M3 - Review article
C2 - 28577718
AN - SCOPUS:85013680737
SN - 0960-7404
VL - 26
SP - 125
EP - 137
JO - Surgical Oncology
JF - Surgical Oncology
IS - 2
ER -